ClinicalTrials.gov
ClinicalTrials.gov Menu

Kabul Vitamin D Supplementation Trial

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00548379
Recruitment Status : Unknown
Verified May 2008 by London School of Hygiene and Tropical Medicine.
Recruitment status was:  Active, not recruiting
First Posted : October 24, 2007
Last Update Posted : May 16, 2008
Sponsor:
Collaborators:
Wellcome Trust
Aga Khan Health Services
Aga Khan University
Maywand Hospital, Kabul
Information provided by:
London School of Hygiene and Tropical Medicine

Brief Summary:

Background: Pneumonia is the leading cause of childhood mortality, accounting for 19% of the 10.6 million deaths that occur each year1. Case-control studies from Ethiopia2 and India3 suggest that sub-clinical vitamin D deficiency may increase ten times the risk of pneumonia in children. We postulate that controlling childhood vitamin D deficiency has the potential to dramatically reduce the incidence of pneumonia and save >700,000 lives each year since vitamin D deficiency is widespread in developing countries.

Aim: To investigate whether 3-monthly oral supplementation of 100,000iu vitamin D reduces pneumonia and its consequences among children aged 1-12 months (followed for 18 months), living in a deprived area of Kabul, Afghanistan, where >70% of young children are vitamin D deficient (<8ng/dl). The effect of vitamin D on the incidence of other diseases, in particular diarrhea and rickets will also be investigated.

Methods: Randomised double-blind placebo-controlled trial: 3000 children will be randomised to receive either 6 doses of vitamin D or placebo. The first dose will be given at the start of autumn and the second and subsequent doses every 3 months thereafter; children will be followed for 18 months. Incidence of pneumonia will be ascertained though weekly home visits (active surveillance) and from attendances and admissions at the trial clinic and wards in the hospital serving the study area (passive surveillance).


Condition or disease Intervention/treatment Phase
Pneumonia Vitamin D Deficiency Drug: vitamin D Drug: placebo Phase 3

  Show Detailed Description

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 3048 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: The Effect of Vitamin D Supplementation on the Incidence of Pneumonia in Children in Afghanistan: a Randomized Controlled Trial
Study Start Date : November 2007
Estimated Primary Completion Date : June 2009
Estimated Study Completion Date : July 2009

Resource links provided by the National Library of Medicine

Drug Information available for: Vitamin D
U.S. FDA Resources

Arm Intervention/treatment
Active Comparator: 1
Vitamin D
Drug: vitamin D
vitamin D 100,000 units once in 3 months
Placebo Comparator: 2 Drug: placebo
olive oil 1ml



Primary Outcome Measures :
  1. incidence of pneumonia [ Time Frame: 18 months ]

Secondary Outcome Measures :
  1. incidence of diarrhoea [ Time Frame: 18 months ]
  2. incidence of ricketts [ Time Frame: 18 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   1 Month to 11 Months   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. 1 to 11 month old infants living in the study area
  2. caretakers are willing to give consent to take part in the study

Exclusion Criteria:

  1. the family is likely to migrate out of the study area within the next 18 months
  2. the child has been diagnosed with rickets or known to have received a course of vitamin D treatment in the past 3 monDths.
  3. Child with Kwashiorkor or Marasmus.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00548379


Locations
Afghanistan
Aga Khan Health Services
Kabul, Afghanistan
Maywand Hospital
Kabul, Afghanistan
Sponsors and Collaborators
London School of Hygiene and Tropical Medicine
Wellcome Trust
Aga Khan Health Services
Aga Khan University
Maywand Hospital, Kabul
Investigators
Principal Investigator: Daniel Chandramohan, MBBS MSc PhD London School of Hygiene and Tropical Medicine
Principal Investigator: Semira Manaseki-Holland, MRCP PhD Agh Khan Health Services
Principal Investigator: Zulfiqar A Bhutta, MD Aga khan University, Karachi
Principal Investigator: Zulf Mughal, MRCP Manchester Childrens Hosptial

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Semira Manaseki-Holland BMSci MBBS MFPHM MRCP MSc PhD, Chief Executive Officer for Central Asia,, Aga Khan Health Services, Afghanistan
ClinicalTrials.gov Identifier: NCT00548379     History of Changes
Other Study ID Numbers: 1963
WT082476MA
First Posted: October 24, 2007    Key Record Dates
Last Update Posted: May 16, 2008
Last Verified: May 2008

Keywords provided by London School of Hygiene and Tropical Medicine:
vitamin D
pneumonia

Additional relevant MeSH terms:
Pneumonia
Vitamin D Deficiency
Lung Diseases
Respiratory Tract Diseases
Respiratory Tract Infections
Avitaminosis
Deficiency Diseases
Malnutrition
Nutrition Disorders
Vitamins
Vitamin D
Ergocalciferols
Micronutrients
Growth Substances
Physiological Effects of Drugs
Bone Density Conservation Agents